F. Hoffmann-La Roche Ag
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$13Mgeneral payments (2019-2025)
$9.8Mresearch payments (2019-2025)
2,880clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Tecentriq $307K associated (2023-2025)
- Ocrevus $294K associated (2023-2025)
- Vabysmo $95K associated (2023-2025)
- Alecensa $93K associated (2023-2025)
- Hemlibra $89K associated (2023-2025)
- Perjeta $88K associated (2023-2025)
- Kadcyla $50K associated (2023-2025)
- Polivy $34K associated (2023-2025)
- Avastin $32K associated (2023-2025)
- Xofluza $26K associated (2023-2025)
- Evrysdi $24K associated (2023-2025)
- Susvimo $13K associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Arshad Khanani | Reno, NV | Ophthalmology | $274,912.79 |
| Srinivas Sadda | Pasadena, CA | Ophthalmology | $210,700.79 |
| Veeral Sheth | Oak Forest, IL | Ophthalmology | $161,207.78 |
| Robert Strieter | Los Angeles, CA | Pulmonary Disease | $158,000.00 |
| Razelle Kurzrock | Milwaukee, WI | Hematology & Oncology | $126,505.24 |
| Karl Csaky | Dallas, TX | Ophthalmology | $116,530.62 |
| Amit Bar-Or | Philadelphia, PA | Neurology (Psychiatry & Neurology) | $102,851.45 |
| Guy Young | Bozeman, MT | Pediatric Hematology-Oncology | $97,218.83 |
| Jeffrey Bennett | Aurora, CO | Neurology (Psychiatry & Neurology) | $95,250.37 |
| Louis Weimer | New York, NY | Neurology (Psychiatry & Neurology) | $88,996.45 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.